PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,043,879 | -20.9% | 359,970 | +3.3% | 0.00% | -25.0% |
| Q2 2023 | $13,965,076 | -1.6% | 348,517 | +0.2% | 0.00% | 0.0% |
| Q1 2023 | $14,197,146 | +7.8% | 347,884 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $13,166,164 | -25.4% | 341,004 | +2.8% | 0.00% | -33.3% |
| Q3 2022 | $17,647,000 | -5.7% | 331,775 | +3.3% | 0.01% | -14.3% |
| Q2 2022 | $18,723,000 | -29.7% | 321,143 | -7.9% | 0.01% | -12.5% |
| Q1 2022 | $26,625,000 | +23.1% | 348,848 | -3.0% | 0.01% | +33.3% |
| Q4 2021 | $21,636,000 | +13.3% | 359,568 | +5.4% | 0.01% | 0.0% |
| Q3 2021 | $19,100,000 | -2.1% | 341,060 | +6.1% | 0.01% | 0.0% |
| Q2 2021 | $19,504,000 | -11.8% | 321,418 | +1.8% | 0.01% | -25.0% |
| Q1 2021 | $22,121,000 | +10.0% | 315,608 | -6.0% | 0.01% | 0.0% |
| Q4 2020 | $20,102,000 | +0.5% | 335,929 | +1.0% | 0.01% | -11.1% |
| Q3 2020 | $20,002,000 | +7.7% | 332,694 | -6.0% | 0.01% | 0.0% |
| Q2 2020 | $18,579,000 | +62.6% | 354,083 | +3.9% | 0.01% | +28.6% |
| Q1 2020 | $11,424,000 | -24.9% | 340,693 | +1.4% | 0.01% | -12.5% |
| Q4 2019 | $15,214,000 | +21.8% | 335,829 | +2.4% | 0.01% | +14.3% |
| Q3 2019 | $12,489,000 | -3.7% | 328,028 | +10.0% | 0.01% | -12.5% |
| Q2 2019 | $12,975,000 | +18.3% | 298,329 | +3.5% | 0.01% | +14.3% |
| Q1 2019 | $10,968,000 | -1.0% | 288,176 | +12.0% | 0.01% | -12.5% |
| Q4 2018 | $11,074,000 | -6.4% | 257,393 | +6.9% | 0.01% | 0.0% |
| Q3 2018 | $11,834,000 | +73.2% | 240,754 | +12.9% | 0.01% | +60.0% |
| Q2 2018 | $6,834,000 | +12.3% | 213,224 | +9.2% | 0.01% | 0.0% |
| Q1 2018 | $6,083,000 | -28.8% | 195,274 | +4.3% | 0.01% | -28.6% |
| Q4 2017 | $8,548,000 | +20.6% | 187,249 | -0.8% | 0.01% | +16.7% |
| Q3 2017 | $7,085,000 | -16.9% | 188,677 | +5.6% | 0.01% | -25.0% |
| Q2 2017 | $8,524,000 | +13.5% | 178,700 | +8.5% | 0.01% | 0.0% |
| Q1 2017 | $7,512,000 | +43.8% | 164,727 | +1.9% | 0.01% | +33.3% |
| Q4 2016 | $5,224,000 | +18.8% | 161,712 | +25.9% | 0.01% | +20.0% |
| Q3 2016 | $4,396,000 | +6.4% | 128,440 | +4.9% | 0.01% | 0.0% |
| Q2 2016 | $4,130,000 | -40.8% | 122,428 | -7.0% | 0.01% | -44.4% |
| Q1 2016 | $6,973,000 | -30.1% | 131,610 | +1.3% | 0.01% | -30.8% |
| Q4 2015 | $9,981,000 | +92.3% | 129,965 | +2.9% | 0.01% | +62.5% |
| Q3 2015 | $5,190,000 | -37.7% | 126,262 | +7.2% | 0.01% | -27.3% |
| Q2 2015 | $8,327,000 | -18.1% | 117,740 | +2.9% | 0.01% | -21.4% |
| Q1 2015 | $10,171,000 | +6.5% | 114,471 | +6.3% | 0.01% | 0.0% |
| Q4 2014 | $9,549,000 | -7.6% | 107,695 | +1.1% | 0.01% | -17.6% |
| Q3 2014 | $10,329,000 | +21.5% | 106,565 | +15.1% | 0.02% | +21.4% |
| Q2 2014 | $8,502,000 | +50.1% | 92,547 | +14.4% | 0.01% | +40.0% |
| Q1 2014 | $5,663,000 | +28.9% | 80,905 | +5.8% | 0.01% | +25.0% |
| Q4 2013 | $4,395,000 | +17.7% | 76,448 | +4.3% | 0.01% | 0.0% |
| Q3 2013 | $3,734,000 | +103.4% | 73,283 | +17.2% | 0.01% | +100.0% |
| Q2 2013 | $1,836,000 | – | 62,511 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |